BIOFILCHEMBiofil Chemicals & Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and packaging solutions. It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Risk gate: safety score is only 18/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Profit growth: -95.3% YoY
- • ROCE: 1.5%
- • Golden cross setup: SMA50 below SMA200
- • Trend strength (ADX): 18
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Revenue growth: 34.0% YoY
- • Debt/Equity: 0.14
- • Promoter holding: 58.1%
- • RSI: 59
Bear case
- • Profit growth: -95.3% YoY
- • ROCE: 1.5%
- • Golden cross setup: SMA50 below SMA200
- • Trend strength (ADX): 18
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Profit growth: -95.3% YoY
- • ROCE: 1.5%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹2.03). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.